We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...

The embedded finance company, which posted a loss last year, hired Citigroup to explore its strategic options and named an ...

William Blair cut their Q2 2026 earnings per share estimates for shares of Oracle in a report issued on Tuesday, March 11th.

Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Agenus in a report issued ...

The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...

William Blair downgraded Udemy (UDMY) to Market Perform from Outperform after the company announced the appointment of Hugo Sarrazin as ...

Fintel reports that on March 12, 2025, William Blair downgraded their outlook for Udemy (NasdaqGS:UDMY) from Outperform to ...

William Blair analyst Andy Hsieh reiterated a Hold rating on Nektar Therapeutics (NKTR – Research Report) today. The company’s shares closed ...

Fintel reports that on March 12, 2025, William Blair downgraded their outlook for Magic Software Enterprises (NasdaqGS:MGIC) ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.

CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a ...